{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T17:14:37Z","timestamp":1789146877917,"version":"build-2803163510"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.lungcan.2026.109589","type":"journal-article","created":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T15:13:15Z","timestamp":1787411595000},"page":"109589","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["First-line pyrotinib plus apatinib in advanced non-small cell lung cancer harboring HER2 mutations or amplification: a phase II trial"],"prefix":"10.1016","volume":"220","author":[{"given":"Yaning","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxin","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangjian","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihua","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junling","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuezhi","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Puyuan","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyu","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linyan","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1743-6383","authenticated-orcid":false,"given":"Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.lungcan.2026.109589_b0005","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/nrc2656","article-title":"Novel anticancer targets: revisiting ERBB2 and discovering ERBB3","volume":"9","author":"Baselga","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.lungcan.2026.109589_b0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102520","article-title":"Targeting HER2 alterations in non-small cell lung cancer: Therapeutic breakthrough and challenges","volume":"114","author":"Yu","year":"2023","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.lungcan.2026.109589_b0015","article-title":"HER2-altered non-small cell lung cancer: biology, clinicopathologic features, and emerging therapies","volume":"12","author":"Yu","year":"2022","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109589_b0020","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1186\/s12885-018-4277-x","article-title":"Outcomes of Pemetrexed-based chemotherapies in HER2-mutant lung cancers","volume":"18","author":"Wang","year":"2018","journal-title":"BMC Cancer"},{"issue":"11","key":"10.1016\/j.lungcan.2026.109589_b0025","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1016\/j.jtho.2021.06.025","article-title":"Efficacy of immune checkpoint inhibitors alone or in combination with chemotherapy in NSCLC harboring ERBB2 mutations","volume":"16","author":"Saalfeld","year":"2021","journal-title":"J Thorac Oncol."},{"key":"10.1016\/j.lungcan.2026.109589_b0030","doi-asserted-by":"crossref","DOI":"10.1177\/17588359221082339","article-title":"First-line immunotherapy or angiogenesis inhibitor plus chemotherapy for HER2-altered NSCLC: a retrospective real-world POLISH study","volume":"14","author":"Yang","year":"2022","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.lungcan.2026.109589_b0035","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920936090","article-title":"Clinical outcomes of patients with HER2-mutant advanced lung cancer: chemotherapies versus HER2-directed therapies","volume":"12","author":"Zhou","year":"2020","journal-title":"Ther. Adv. Med. Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2026.109589_b0040","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1093\/annonc\/mdv573","article-title":"Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort","volume":"27","author":"Mazieres","year":"2016","journal-title":"Ann. Oncol."},{"issue":"6","key":"10.1016\/j.lungcan.2026.109589_b0045","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/j.jtho.2019.02.017","article-title":"Afatinib in NSCLC With HER2 mutations: results of the prospective, open-label phase II NICHE trial of european thoracic oncology platform (ETOP)","volume":"14","author":"Dziadziuszko","year":"2019","journal-title":"J. Thorac. Oncol."},{"issue":"7","key":"10.1016\/j.lungcan.2026.109589_b0050","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1093\/annonc\/mdv186","article-title":"Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors","volume":"26","author":"Kris","year":"2015","journal-title":"Ann. Oncol."},{"issue":"7691","key":"10.1016\/j.lungcan.2026.109589_b0055","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/nature25475","article-title":"HER kinase inhibition in patients with HER2- and HER3-mutant cancers","volume":"554","author":"Hyman","year":"2018","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.lungcan.2026.109589_b0060","doi-asserted-by":"crossref","first-page":"S358","DOI":"10.1016\/j.jtho.2016.11.398","article-title":"MA04.02 Neratinib \u00b1 temsirolimus in HER2-mutant lung cancers: an international, randomized phase II study","volume":"12","author":"Gandhi","year":"2017","journal-title":"J. Thor. Oncol."},{"key":"10.1016\/j.lungcan.2026.109589_b0065","doi-asserted-by":"crossref","first-page":"S1616","DOI":"10.1016\/j.annonc.2025.09.088","article-title":"LBA74 Zongertinib as first-line treatment in patients with advanced HER2-mutant NSCLC: beamion LUNG 1","volume":"36","author":"Popat","year":"2025","journal-title":"Ann. Oncol."},{"issue":"18","key":"10.1016\/j.lungcan.2026.109589_b0070","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1056\/NEJMoa2511065","article-title":"Sevabertinib in advanced HER2-mutant non-small-cell lung cancer","volume":"393","author":"Le","year":"2025","journal-title":"N Engl J Med."},{"issue":"24","key":"10.1016\/j.lungcan.2026.109589_b0075","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1200\/JCO.20.00297","article-title":"Pyrotinib in HER2-mutant advanced lung adenocarcinoma after platinum-based chemotherapy: a multicenter, open-label, single-arm","volume":"38","author":"Zhou","year":"2020","journal-title":"Phase II Study. J Clin Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109589_b0080","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s12916-022-02245-z","article-title":"Efficacy and safety of pyrotinib in advanced lung adenocarcinoma with HER2 mutations: a multicenter, single-arm, phase II trial","volume":"20","author":"Song","year":"2022","journal-title":"BMC Med."},{"issue":"8","key":"10.1016\/j.lungcan.2026.109589_b0085","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1038\/s41591-023-02461-x","article-title":"First-line pyrotinib in advanced HER2-mutant non-small-cell lung cancer: a patient-centric phase 2 trial","volume":"29","author":"Liu","year":"2023","journal-title":"Nat. Med."},{"issue":"2","key":"10.1016\/j.lungcan.2026.109589_b0090","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1007\/s10120-020-01126-9","article-title":"Apatinib exhibits synergistic effect with pyrotinib and reverses acquired pyrotinib resistance in HER2-positive gastric cancer via stem cell factor\/c-kit signaling and its downstream pathways","volume":"24","author":"Su","year":"2021","journal-title":"Gastric Cancer"},{"issue":"4","key":"10.1016\/j.lungcan.2026.109589_b0095","first-page":"139","article-title":"Pyrotinib in HER2 heterogeneously mutated or amplified advanced non-small cell lung cancer patients: a retrospective real-world study (PEARL)","volume":"1","author":"Yang","year":"2021","journal-title":"J. Natl. Cancer Cent."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109589_b0100","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1186\/s12916-022-02470-6","article-title":"Pyrotinib combined with apatinib for targeting metastatic non-small cell lung cancer with HER2 alterations: a prospective, open-label, single-arm phase 2 study (PATHER2)","volume":"20","author":"Yang","year":"2022","journal-title":"BMC Med."},{"key":"10.1016\/j.lungcan.2026.109589_b0105","first-page":"9","article-title":"Revising the declaration of helsinki","volume":"158","author":"World Medical A","year":"2000","journal-title":"Bull. Med. Ethics"},{"issue":"11","key":"10.1016\/j.lungcan.2026.109589_b0110","doi-asserted-by":"crossref","first-page":"e108","DOI":"10.1093\/nar\/gkw227","article-title":"VarDict: a novel and versatile variant caller for next-generation sequencing in cancer research","volume":"44","author":"Lai","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.lungcan.2026.109589_b0115","series-title":"Genomics in the cloud : using Docker, GATK, and WDL in Terra","author":"Gvd","year":"2020"},{"issue":"23","key":"10.1016\/j.lungcan.2026.109589_b0120","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1093\/bioinformatics\/btu549","article-title":"FACTERA: a practical method for the discovery of genomic rearrangements at breakpoint resolution","volume":"30","author":"Newman","year":"2014","journal-title":"Bioinformatics"},{"issue":"1","key":"10.1016\/j.lungcan.2026.109589_b0125","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s13059-016-0974-4","article-title":"The ensembl variant effect predictor","volume":"17","author":"McLaren","year":"2016","journal-title":"Genome Biol."},{"issue":"5","key":"10.1016\/j.lungcan.2026.109589_b0130","doi-asserted-by":"crossref","DOI":"10.3390\/genes11050585","article-title":"The FANC\/BRCA pathway releases replication blockades by eliminating DNA interstrand cross-links","volume":"11","author":"Renaudin","year":"2020","journal-title":"Genes (Basel)"},{"issue":"3","key":"10.1016\/j.lungcan.2026.109589_b0135","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2022111998","article-title":"WRN helicase and mismatch repair complexes independently and synergistically disrupt cruciform DNA structures","volume":"42","author":"Mengoli","year":"2023","journal-title":"The EMBO Journal"},{"issue":"27","key":"10.1016\/j.lungcan.2026.109589_b0140","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1200\/JCO.2012.44.2806","article-title":"Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations","volume":"31","author":"Sequist","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.lungcan.2026.109589_b0145","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/S1470-2045(17)30608-3","article-title":"Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial","volume":"18","author":"Wu","year":"2017","journal-title":"Lancet Oncol."},{"issue":"23","key":"10.1016\/j.lungcan.2026.109589_b0150","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1056\/NEJMoa2503704","article-title":"Zongertinib in previously treated HER2-mutant non-small-cell lung cancer","volume":"392","author":"Heymach","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2026.109589_b0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2026.104783","article-title":"Association between diarrhea and survival in patients with HER2-positive advanced breast cancer treated with pyrotinib-based therapy: a landmark analysis from the real-world PRETTY study","volume":"87","author":"Li","year":"2026","journal-title":"Breast"},{"issue":"3","key":"10.1016\/j.lungcan.2026.109589_b0160","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa2112431","article-title":"Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer","volume":"386","author":"Li","year":"2022","journal-title":"N Engl J Med."},{"issue":"16_suppl","key":"10.1016\/j.lungcan.2026.109589_b0165","doi-asserted-by":"crossref","first-page":"8543","DOI":"10.1200\/JCO.2024.42.16_suppl.8543","article-title":"Trastuzumab deruxtecan (T-DXd) in patients with HER2-mutant metastatic non\u2013small cell lung cancer (mNSCLC): final analysis results of DESTINY-Lung02","volume":"42","author":"Janne","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"16_suppl","key":"10.1016\/j.lungcan.2026.109589_b0170","volume":"40","author":"Li","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.lungcan.2026.109589_b0175","first-page":"1873","article-title":"Interstitial Lung disease induced by anti-ERBB2 antibody-drug conjugates: a review","volume":"7","author":"Tarantino","year":"2021","journal-title":"J. Am. Med. Assoc. Oncol."},{"issue":"17","key":"10.1016\/j.lungcan.2026.109589_b0180","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMoa2516969","article-title":"First-line zongertinib in advanced HER2-mutant non-small-cell lung cancer","volume":"394","author":"Heymach","year":"2026","journal-title":"N. Engl. J. Med."},{"issue":"16_suppl","key":"10.1016\/j.lungcan.2026.109589_b0185","volume":"42","author":"Johnson","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"16_suppl","key":"10.1016\/j.lungcan.2026.109589_b0190","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS8648","article-title":"SOHO-02: Phase III trial of BAY 2927088 in patients with locally advanced or metastatic NSCLC with HER2-activating mutations","volume":"43","author":"Le","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"8_Supplement","key":"10.1016\/j.lungcan.2026.109589_b0195","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2026-CT301","article-title":"Abstract CT301: SHR-A1811 \u00b1 adebrelimab as first-line (1\u00a0L) treatment for advanced HER2-mutant NSCLC: a randomized phase 2 cohort from a phase 1b\/2 study","volume":"86","author":"Lu","year":"2026","journal-title":"Cancer Res."},{"issue":"11","key":"10.1016\/j.lungcan.2026.109589_b0200","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.21037\/tlcr-24-828","article-title":"The latest advances in liquid biopsy for lung cancer-a narrative review","volume":"13","author":"She","year":"2024","journal-title":"Transl. Lung Cancer Res."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109589_b0205","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s40164-023-00417-y","article-title":"Molecular correlation of response to pyrotinib in advanced NSCLC with HER2 mutation: biomarker analysis from two phase II trials","volume":"12","author":"Mao","year":"2023","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.lungcan.2026.109589_b0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2024.108062","article-title":"Dynamic characterization of circulating tumor DNA in HER2-altered advanced non-small cell lung cancer treated with pyrotinib and apatinib: exploratory biomarker analysis from PATHER2 study","volume":"200","author":"Dong","year":"2025","journal-title":"Lung Cancer"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226006501?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226006501?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T16:54:59Z","timestamp":1789145699000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500226006501"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":42,"alternative-id":["S0169500226006501"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109589","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"First-line pyrotinib plus apatinib in advanced non-small cell lung cancer harboring HER2 mutations or amplification: a phase II trial","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109589","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"109589"}}